leadf
logo-loader
viewFutura Medical PLC

Futura Medical has early success with new CBD gel

It has just completed initial laboratory and optimisation work on the new product

Futura Medical PLC -

Futura Medical PLC (LON:FUM) said its technology used to deliver pain medication and sexual health treatments through the skin barrier is proving successful in the field of cannabidiol (CBD).

It has just completed initial laboratory and optimisation work on a gel called CBD100 using its DermaSys discovery to carry the payload.

The lab work on human epidermis demonstrated “highly efficient penetration of cannabidiol into and through the skin”. Indeed, the approach was “superior to an established, marketed, comparator product”.

Cannabidiol is known to be unstable with many common ingredients it is formulated with to make it easier to take. However, the DermaSys gel was specially formulated to minimised these issues, investors were told.

Futura has now started to explore commercialisation options for CBD100 with joint-venture partner CBDerma as stability work continues in parallel.

In a statement, Futura chief executive James Barder said: “We are aiming for CBD100 to be highly differentiated from existing, largely un-regulated, low-tech products in the fast growing cannabidiol market on the basis of quality, stability and efficient delivery to the skin for a number of applications and indications expected to range from cosmeceutical through to pharmaceutical dermal and pain relief treatments.”

Futura’s flagship innovation is a phase III gel called MED3000 that uses DermaSys to treat erectile dysfunction.

Quick facts: Futura Medical PLC

Price: 15 GBX

AIM:FUM
Market: AIM
Market Cap: £36.84 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Futura Medical PLC named herein, including the promotion by the Company of Futura Medical PLC in any Content on the Site, the Company receives...

FOR OUR FULL DISCLAIMER CLICK HERE

Futura Medical kicks off work on Phase III trial for erectile dysfunction gel

James Barder, chief executive of Futura Medical PLC (LON:FUM), tells Proactive they've begun preparatory work on the first Phase III efficacy trial for MED2002 - their topical gel for erectile dysfunction (ED). The study will recruit approximately 1,000 patients with mild, moderate and...

on 27/4/18

2 min read